Jim Simons’s 89bio ETNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-510,500
| Closed | -$7.5M | – | 3384 |
|
|
2025
Q3 | $7.5M | Sell |
510,500
-2,900
| -0.6% | -$29.6K | 0.01% | 1241 |
|
|
2025
Q2 | $5.04M | Buy |
513,400
+9,100
| +2% | +$75.3K | 0.01% | 1525 |
|
|
2025
Q1 | $3.67M | Buy |
504,300
+206,600
| +69% | +$1.81M | 0.01% | 1611 |
|
|
2024
Q4 | $2.33M | Sell |
297,700
-14,324
| -5% | -$118K | ﹤0.01% | 1959 |
|
|
2024
Q3 | $2.31M | Buy |
312,024
+32,624
| +12% | +$274K | ﹤0.01% | 1926 |
|
|
2024
Q2 | $2.24M | Buy |
+279,400
| New | +$2.49M | ﹤0.01% | 1817 |
|
|
2023
Q2 | – | Sell |
-13,900
| Closed | -$212K | – | 4021 |
|
|
2023
Q1 | $212K | Sell |
13,900
-201,267
| -94% | -$2.62M | ﹤0.01% | 3253 |
|
|
2022
Q4 | $2.74M | Sell |
215,167
-18,600
| -8% | -$167K | ﹤0.01% | 1885 |
|
|
2022
Q3 | $1.35M | Sell |
233,767
-71,100
| -23% | -$312K | ﹤0.01% | 2302 |
|
|
2022
Q2 | $982K | Buy |
304,867
+41,467
| +16% | +$125K | ﹤0.01% | 2737 |
|
|
2022
Q1 | $993K | Buy |
+263,400
| New | +$1.7M | ﹤0.01% | 2731 |
|
|
2021
Q1 | – | Sell |
-37,230
| Closed | -$907K | – | 3427 |
|
|
2020
Q4 | $907K | Buy |
+37,230
| New | +$952K | ﹤0.01% | 2551 |
|
Other funds holding ETNB
Jim Simons's ETNB Position: Q4 2025 in Review
Jim Simons sold out of 89bio (ETNB) in Q4 2025, closing a stake of 510,500 shares — an estimated $7.5M sold.
Jim Simons first reported a position in ETNB in Q4 2020 and held it in 12 quarters. The position peaked at $7.5M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.
- Jim Simons reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
- Jim Simons sold 510,500 89bio shares in Q4 2025, an estimated $7.5M.
- Jim Simons first reported a position in 89bio in Q4 2020 and held it in 12 quarters.
- Jim Simons's 89bio position peaked at $7.5M in Q3 2025.
- 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.
Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.